BRIEF-Lexicon Pharmaceuticals And Novo Nordisk Announce Initiation Of Phase 1 Study With Oral Obesity Drug Candidate LX9851

Lexicon Pharmaceuticals, Inc. -3.05%

Lexicon Pharmaceuticals, Inc.

LXRX

1.59

-3.05%

March 23 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:

  • LEXICON PHARMACEUTICALS AND NOVO NORDISK ANNOUNCE INITIATION OF PHASE 1 STUDY WITH ORAL OBESITY DRUG CANDIDATE LX9851

  • LEXICON PHARMACEUTICALS INC - EARNS SECOND $10 MILLION MILESTONE; ELIGIBLE FOR UP TO $1 BILLION IN PAYMENTS

  • LEXICON PHARMACEUTICALS INC - PHASE 1 STUDY OF LX9851 EXPECTED TO COMPLETE IN Q1 2027

Source text: ID:nGNX37N8nH

Further company coverage: LXRX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.